Drugs / CBP-4888
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05881993 | May 2023 → May 2024 | — | Comanche Biopharma | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07282171 | Feb 2025 → Mar 2027 expected | preeclampsia | Comanche Biopharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-08 | Comanche Biopharma | Regulatory Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia comanchebiopharma.com ↗
Comanche Biopharma Corp. today announced that the European Medicines Agency (EMA) has granted orphan drug designation for CBP-4888 for the treatment of sFlt1-mediated preterm preeclampsia. |
| 2025-01-30 | Comanche Biopharma | Regulatory Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia comanchebiopharma.com ↗
Comanche Biopharma Corp. today announced that the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group has awarded an Innovation Passport to CBP-4888, Comanche Biopharma’s investigational drug candidate for the treatment of sFlt1-mediated preterm preeclampsia. |
| 2023-08-23 | Comanche Biopharma | Regulatory Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia comanchebiopharma.com ↗
Comanche Biopharma Corp. today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA)for the investigation of CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. |
| 2023-03-30 | Comanche Biopharma | Regulatory Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP- 4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia comanchebiopharma.com ↗
Comanche Biopharma Corp. , a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for Comanche’s novel, siRNA therapy to treat preeclampsia. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP-4888 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05881993 ↗ |
| Route | Subcutaneous | “CBP-4888 administered once as a subcutaneous dose.” NCT05881993 ↗ |